Investor Overview

Neovasc is a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina. The company currently has two devices. The Reducer is CE-marked in the European Union and under FDA review for the treatment of refractory angina. The Reducer provides relief of angina symptoms by altering blood flow in the heart’s circulatory system, thereby increasing the perfusion of oxygenated blood to ischemic areas of the heart muscle. Tiara is a self-expanding mitral bioprosthesis for treatment of mitral valve regurgitation (“MR”) by replacing the diseased valve.

Conventional surgical treatments are only appropriate for about half of MR patients, who number an estimated four million in the U.S. with a similar number of patients in Europe. Tiara is implanted using a minimally invasive, transcatheter approach which avoids open-heart surgery or use of a cardiac bypass machine. The Tiara valve is not commercially available and is currently being evaluated in two ongoing clinical trials in the US, CA, Europe and Israel.


detail >


detail >

Latest News

Neovasc Comments on EuroIntervention Article

> read full release

Archive >

Presentations and Events

Neovasc Q4 2020 Earnings Call

Thursday, March 11, 2021, 4:30 p.m. ET

webcast >

H.C. Wainwright Global Life Sciences Conference -- March 9-10, 2021 (Virtual)

on-demand webcast >
recent presentations and events >

Neovasc Q4 2020 Earnings Call

Thursday, March 11, 2021
4:30 p.m. ET



webcast >

Neovasc Presentation at Bioconnect Conference 2021




watch it here >

Financial Report Archives

2020 Financial Reports

News Release Archives

2021 News Releases

Share Information

Grant Thornton LLP, Vancouver, BC

Legal Counsel
Blakes LLP, Vancouver, BC

Transfer Agent
Computershare, Vancouver, BC

Investor Relations
Chris Clark, Chief Financial Officer

To receive news updates via email;

register now